Enanta Pharmaceuticals, Inc. (ENTA)

Enanta Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is October - September.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	285	235	1,075	1,148	919	1,182
Market Cap Growth	-56.27%	-78.12%	-6.39%	24.98%	-22.29%	-28.59%
Enterprise Value	28	-112	847	909	540	847
PE Ratio	-	-1.76	-8.83	-14.54	-25.41	25.49
PS Ratio	3.91	2.97	12.48	11.83	7.50	5.76
PB Ratio	1.71	1.09	3.35	2.88	2.02	2.56
P/FCF Ratio	-3.26	-2.10	-12.37	-16.23	162.84	17.92
P/OCF Ratio	-3.44	-2.28	-12.68	-16.41	129.64	16.56
EV/Sales Ratio	0.38	-1.42	9.83	9.37	4.41	4.13
EV/EBITDA Ratio	-0.96	0.91	-7.11	-8.72	-17.20	17.34
EV/EBIT Ratio	-0.94	0.89	-6.93	-8.45	-15.41	18.58
EV/FCF Ratio	-0.99	1.00	-9.75	-12.85	95.65	12.83
Debt / Equity Ratio	0.28	0.12	0.08	0.01	0.02	-
Debt / EBITDA Ratio	-0.40	-0.21	-0.21	-0.05	-0.26	-
Debt / FCF Ratio	-0.41	-0.24	-0.29	-0.08	1.44	-
Quick Ratio	5.71	6.09	9.17	7.41	17.00	17.12
Current Ratio	6.43	6.73	10.45	8.82	18.08	17.77
Asset Turnover	0.16	0.19	0.21	0.21	0.24	0.44
Interest Coverage	-10.65	-24.45	-	-	-	-
Return on Equity (ROE)	-64.90%	-52.20%	-34.70%	-18.50%	-7.60%	10.50%
Return on Assets (ROA)	-29.30%	-32.80%	-30.30%	-17.20%	-7.20%	9.90%
Return on Capital (ROIC)	-63.53%	-56.41%	-35.73%	-27.07%	-8.98%	8.09%
Earnings Yield	-46.25%	-56.90%	-11.33%	-6.88%	-3.94%	3.92%
FCF Yield	-39.77%	-47.71%	-8.08%	-6.16%	0.61%	5.58%
Buyback Yield / Dilution	-0.63%	-1.78%	-2.14%	-1.16%	4.90%	-1.54%
Total Shareholder Return	-0.63%	-1.78%	-2.14%	-1.16%	4.90%	-1.54%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).